| [1] |
Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study [J]. Kidney Int，2003, 64(2):610-615.
|
| [2] |
Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey [J]. J Am Soc Nephrol, 2002, 13(2):504-510.
|
| [3] |
Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron [J]. J Nephrol, 2006, 19(2):161-167.
|
| [4] |
Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients [J]. Nephrol Dial Transplant, 1996, 11(6):1079-1083.
|
| [5] |
Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin [J]. Kidney Int, 1996, 50(5):1694-1699.
|
| [6] |
Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin [J]. J Assoc Physicians India, 2003, 51:170-174.
|
| [7] |
Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease [J]. Am J Nephrol, 2006, 26(5):445-454.
|
| [8] |
Fishbane S. Safety in iron management [J]. Am J Kidney Dis, 2003, 41(5 Suppl):18-26.
|
| [9] |
Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis [J]. Am J Kidney Dis, 2008, 52(5):897-906.
|
| [10] |
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses [J]. BMJ, 2003, 327(7414):557-560.
|
| [11] |
Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin [J]. Nephrol Dial Transplant, 2001, 16(5):967-974.
|
| [12] |
Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis [J]. Nephron Clin Pract, 2005, 100(3):c55-c62.
|
| [13] |
Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis-dependent CKD [J]. Kidney Int, 2005, 68(6):2846-2856.
|
| [14] |
Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients [J]. Nephrol Dial Transplant, 2011, 26(5):1599-1607.
|
| [15] |
Nagaraju SP, Cohn A, Akbari A, et al. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial [J]. BMC Nephrol, 2013, 14:64.
|
| [16] |
Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia [J]. Nephrol Dial Transplant, 2014, 29(11):2075-2084.
|
| [17] |
Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease [J]. Kidney Int, 2015, 88(4):905-914.
|
| [18] |
Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial [J]. Nephrol Dial Transplant, 2015, 30(4):645-652.
|
| [19] |
Spinowitz B BA, Bolton WK PB, Provenzano R RM, et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis- evaluation of safety and efficacy in two phase Ⅲ studies [J]. J Am Soc Nephrol, 2006, 17:324.
|
| [20] |
Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present, and future [J]. Biochim Biophys Acta, 2010, 1800(8):760-769.
|
| [21] |
Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing [J]. Clin J Am Soc Nephrol, 2015, 10(10):1814-1821.
|
| [22] |
Del VL, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease [J]. Clin Kidney J, 2016, 9(2):260-267.
|